Delving into the Latest Updates on Shanghai Pailong Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3
Chemical drugs	2

Top 5 Target	Count

PPI(Cyclophilin peptidylprolyl isomerases)	1
PARP7(TCDD-inducible poly [ADP-ribose] polymerase)	1
KIF18A(kinesin family member 18A)	1
PRMT5(Protein arginine methyltransferase 5)	1
CDK7(Cyclin-dependent kinase 7)	1

Ia期（剂量递增阶段）（1）主要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确定扩展期推荐剂量（RDEs）或最大耐受剂量（MTD）（如存在）。（2）次要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性。（3）探索性目的：探索与GTA182疗效相关的生物标志物。Ib期（剂量扩展阶段）（1）主要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确认II期推荐剂量（RP2D）。（2）次要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性，为后续临床试验推荐剂量和适应症选择提供依据。（3）探索性目的：探索与GTA182疗效相关的生物标志物。

[Translation]

Phase Ia (dose escalation phase) (1) Primary objective: To evaluate the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors to determine the recommended dose (RDEs) or maximum tolerated dose (MTD) for the extension phase (if any). (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 in subjects with MTAPnull/lost advanced solid tumors; To evaluate the preliminary efficacy of GTA182 in subjects with MTAPnull/lost advanced solid tumors. (3) Exploratory objective: To explore biomarkers associated with the efficacy of GTA182. Phase Ib (dose expansion phase) (1) Primary objective: To evaluate the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors at the RDEs dose to confirm the recommended dose for Phase II (RP2D). (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 at RDEs doses in subjects with MTAPnull/lost advanced solid tumors; To evaluate the preliminary efficacy of GTA182 at RDEs doses in subjects with MTAPnull/lost advanced solid tumors, and to provide a basis for the recommended dose and indication selection for subsequent clinical trials. (3) Exploratory objectives: To explore biomarkers associated with the efficacy of GTA182.

Start Date-

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Pailong Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GTAEXS-617 ( CDK7 )	Advanced Malignant Solid Neoplasm More	Phase 2 Clinical
GTA-182 ( PRMT5 )	Advanced Malignant Solid Neoplasm More	Phase 1
PPI modulator(Shanghai Pailong Biotechnology) ( PPI )	Neoplasms More	Preclinical
PARP-7 inhibitors(Apeiron Therapeutics) ( PARP7 )	Neoplasms More	Discovery
KIF18A inhibitors(Apeiron Therapeutics) ( KIF18A )	Uterine Cervical Dysplasia More	Discovery